Zeria Pharmaceutical Co., Ltd. (4559) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Zeria Pharmaceutical Co., Ltd. (4559:JPX), powered by AI.

Current Price
¥2,108
P/E Ratio
9.4
Market Cap
92.9B
Sector
Healthcare
What is the Zeria Pharmaceutical Co., Ltd. stock price forecast?

Zeria Pharmaceutical Co., Ltd. is currently trading at ¥2,108. View real-time AI analysis on Alpha Lenz.

What is Zeria Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Zeria Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Zeria Pharmaceutical Co., Ltd.'s P/E ratio?

Zeria Pharmaceutical Co., Ltd.'s P/E ratio is 9.4.

Zeria Pharmaceutical Co., Ltd.

JPX · 4559
¥2,108-35(-1.63%)Market closedJPX regular session 09:00–15:00 JST
Ask about Zeria Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Zeria Pharmaceutical Co., Ltd. trades at a P/E of 9.4 (undervalued) with solid ROE of 11.7%. 3Y revenue CAGR of 13.6% highlights clear growth momentum.

Ask for details

Company Overview

Zeria Pharmaceutical Co., Ltd. is a prominent entity within the pharmaceutical industry, primarily engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company is distinguished for its focus on gastrointestinal, urological, and detoxification treatments, providing a range of therapeutic drugs aimed at addressing complex medical needs. Beyond prescription medications, Zeria also produces over-the-counter products, expanding its reach to general consumers seeking accessible healthcare solutions. Founded in Japan and deeply rooted in the region, Zeria plays a significant role in the Asian pharmaceutical market, contributing to health advancements through innovation and rigorous scientific inquiry. Its commitment to quality and efficacy positions Zeria as a reliable partner in health, impacting both individual health outcomes and broader public health landscapes. By integrating traditional pharmaceutical methods with cutting-edge research, Zeria Pharmaceutical Co., Ltd. continues to advance in its mission to improve patient lives across varied sectors of healthcare.

CEOMr. Sachiaki Ibe
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees1,746

Company Statistics

FY 2025

Profile

¥92,918,856,632Market Cap
¥87,311,137,000Revenue
0.00Shares Out
1,746Employees

Margins

73.25%Gross
23.88%EBITDA
13.97%Operating
14.45%Pre-Tax
11.42%Net

Valuation

9.35P/E
1.04P/B
1.06EV/Sales
5.31EV/EBITDA
9.12P/FCF

Growth (CAGR)

13.62%Rev 3Yr
7.64%Rev 5Yr
24.20%Op Inc 3Yr
24.40%Op Inc 5Yr
35.86%Net Inc 3Yr
27.67%Net Inc 5Yr

Returns

6.44%ROA
11.75%ROE
8.44%ROIC

Financial Health

¥23,592,676,000Cash & Cash Equivalents
¥45,781,893,000Net Debt
77.26%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Zeria Pharmaceutical Co., Ltd. (ticker: 4559) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 1,746 employees. Market cap is $92.9B.

The current price is 2,108 with a P/E ratio of 9.35x and P/B of 1.04x.

ROE is 11.75% and operating margin is 13.97%. Annual revenue is $87.3B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Zeria Pharmaceutical Co., Ltd. (4559) Stock Forecast 2026 ¥2,108 — Price, Financials & Analyst Targets | Alpha Lenz